RU2006140257A - Моноклональные антитела к фактору роста гепатоцитов - Google Patents
Моноклональные антитела к фактору роста гепатоцитов Download PDFInfo
- Publication number
- RU2006140257A RU2006140257A RU2006140257/13A RU2006140257A RU2006140257A RU 2006140257 A RU2006140257 A RU 2006140257A RU 2006140257/13 A RU2006140257/13 A RU 2006140257/13A RU 2006140257 A RU2006140257 A RU 2006140257A RU 2006140257 A RU2006140257 A RU 2006140257A
- Authority
- RU
- Russia
- Prior art keywords
- mat according
- hgf
- inhibits
- mab
- human
- Prior art date
Links
- 239000003102 growth factor Substances 0.000 title 1
- 210000003494 hepatocyte Anatomy 0.000 title 1
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 claims abstract 8
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims abstract 8
- 238000000034 method Methods 0.000 claims abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 4
- 230000003472 neutralizing effect Effects 0.000 claims abstract 2
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 102000057308 human HGF Human genes 0.000 claims 2
- 241000699666 Mus <mouse, genus> Species 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Claims (20)
1. Моноклональное антитело (мАт), которое связывается с человеческим фактором роста гепатоцитов (HGF) и нейтрализует его.
2. МАт по п.1, которое является химерным.
3. МАт по п.1, которое является гуманизированным.
4. МАт по п.1, которое является человеческим.
5. МАт по п.1, которое ингибирует связывание HGF с cMet по меньшей мере на 50%.
6. МАт по п.1, которое ингибирует HGF-индуцированное рассеивание клеток почки собаки Madin-Darby.
7. МАт по п.1, которое ингибирует HGF-индуцированную пролиферацию клеток HUVEC.
8. МАт по п.1, которое ингибирует HGF-индуцированный ангиогенез.
9. МАт по п.1, которое нейтрализует все виды биологической активности HGF.
10. МАт по п.1, которое ингибирует рост ксенотрансплантата опухоли человека в мыши.
11. МАт по п.10, которое полностью ингибирует рост ксенотрансплантата опухоли человека в мыши.
12. МАт по п.1, которое представляет собой Fab или F(ab')2 фрагмент или одноцепочечное антитело.
13. МАт по п.1, которое специфически связывается с HGF с показателем аффинности связывания, равным по меньшей мере 108 М-1.
14. Химерное или гуманизированное мАт L2G7.
15. Антитело, которое конкурирует с антителом по п.14 за связывание с человеческим HGF.
16. Клеточная линия, продуцирующая мАт по п.1.
17. Фармацевтическая композиция, содержащая мАт по п.14.
18. Способ лечения рака у пациента, предусматривающий введение пациенту фармацевтической композиции, содержащей нейтрализующее анти-HGF мАт.
19. Способ по п.18, отличающийся тем, что указанный рак представляет собой глиобластому.
20. Способ по п.18, отличающийся тем, что указанное мАт является химерным или гуманизированным мАт L2G7.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/825,060 | 2004-04-15 | ||
| US10/825,060 US20040208876A1 (en) | 2003-04-18 | 2004-04-15 | Monoclonal antibodies to hepatocyte growth factor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2006140257A true RU2006140257A (ru) | 2008-05-20 |
| RU2361879C2 RU2361879C2 (ru) | 2009-07-20 |
Family
ID=35320045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006140257/13A RU2361879C2 (ru) | 2004-04-15 | 2004-08-13 | Моноклональные антитела к фактору роста гепатоцитов |
Country Status (25)
| Country | Link |
|---|---|
| US (5) | US20040208876A1 (ru) |
| EP (2) | EP1734995B1 (ru) |
| JP (2) | JP4594381B2 (ru) |
| KR (1) | KR101072736B1 (ru) |
| CN (1) | CN1964738A (ru) |
| AT (1) | ATE473760T1 (ru) |
| AU (1) | AU2004319276C1 (ru) |
| BR (1) | BRPI0418745A (ru) |
| CA (1) | CA2563080C (ru) |
| CR (1) | CR8698A (ru) |
| CY (1) | CY1110783T1 (ru) |
| DE (1) | DE602004028168D1 (ru) |
| DK (1) | DK1734995T3 (ru) |
| ES (1) | ES2346886T3 (ru) |
| HR (1) | HRP20100521T1 (ru) |
| IL (1) | IL178474A (ru) |
| MX (1) | MXPA06011822A (ru) |
| NO (1) | NO20065227L (ru) |
| NZ (1) | NZ550324A (ru) |
| PL (1) | PL1734995T3 (ru) |
| PT (1) | PT1734995E (ru) |
| RU (1) | RU2361879C2 (ru) |
| SI (1) | SI1734995T1 (ru) |
| WO (1) | WO2005107800A1 (ru) |
| ZA (1) | ZA200609407B (ru) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040208876A1 (en) * | 2003-04-18 | 2004-10-21 | Kim Kyung Jin | Monoclonal antibodies to hepatocyte growth factor |
| PL1648998T3 (pl) * | 2003-07-18 | 2015-03-31 | Amgen Inc | Specyficzne czynniki wiążące czynnik wzrostu hepatocytów |
| ZA200701656B (en) * | 2004-08-05 | 2008-09-25 | Genentech Inc | Humanized anti-cment antagonists |
| MX2007015056A (es) * | 2005-06-02 | 2008-03-11 | Galaxy Biotech Llc | Metodos para el tratamiento de tumores de cerebro con anticuerpos. |
| BRPI0617378B8 (pt) | 2005-10-14 | 2022-09-20 | Chugai Pharmaceutical Co Ltd | Uso de um inibidor de il-6 para produzir uma composição farmacêutica para suprimir dano a um ilhota transplantada depois do transplante de ilhota; e aperfeiçoar a viabilidade de uma ilhota em um transplante de ilhota |
| US8945558B2 (en) | 2005-10-21 | 2015-02-03 | Chugai Seiyaku Kabushiki Kaisha | Methods for treating myocardial infarction comprising administering an IL-6 inhibitor |
| AR057582A1 (es) | 2005-11-15 | 2007-12-05 | Nat Hospital Organization | Agentes para suprimir la induccion de linfocitos t citotoxicos |
| EP1967209B1 (en) * | 2005-11-25 | 2012-06-06 | Keio University | Therapeutic agent for prostate cancer |
| CN104189907A (zh) | 2006-01-27 | 2014-12-10 | 学校法人庆应义塾 | 伴有脉络膜血管生成的疾病的治疗药 |
| AR059922A1 (es) * | 2006-04-01 | 2008-05-07 | Galaxy Biotech Llc | Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos |
| JP5754875B2 (ja) | 2006-04-07 | 2015-07-29 | 国立大学法人大阪大学 | 筋再生促進剤 |
| AU2007254942B2 (en) | 2006-06-02 | 2011-10-27 | Aveo Pharmaceuticals, Inc. | Hepatocyte growth factor (HGF) binding proteins |
| AR061170A1 (es) | 2006-06-02 | 2008-08-06 | Aveo Pharmaceuticals Inc | Proteinas que se unen con el factor de crecimiento de hepatocitos (hgf) |
| CA2675625C (en) | 2007-01-23 | 2016-09-13 | Shinshu University | Chronic rejection inhibitor |
| JP5513380B2 (ja) * | 2007-06-25 | 2014-06-04 | アムジエン・インコーポレーテツド | 肝細胞増殖因子に対する特異的結合剤の組成物 |
| TW201002346A (en) * | 2008-04-11 | 2010-01-16 | Galaxy Biotech Llc | Combination of HGF inhibitor and EGF inhibitor to treat cancer |
| WO2009140549A1 (en) * | 2008-05-14 | 2009-11-19 | Amgen Inc. | Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer |
| TW201503898A (zh) | 2008-06-05 | 2015-02-01 | Chugai Pharmaceutical Co Ltd | 神經浸潤抑制劑 |
| PA8849001A1 (es) | 2008-11-21 | 2010-06-28 | Lilly Co Eli | Anticuerpos de c-met |
| US8545839B2 (en) * | 2008-12-02 | 2013-10-01 | Pierre Fabre Medicament | Anti-c-Met antibody |
| US20120052064A1 (en) * | 2009-04-17 | 2012-03-01 | Yuuki Ito | Anti-hgf antibody combinational cancer therapies |
| CN101555912B (zh) * | 2009-04-29 | 2012-10-03 | 深圳市特辰科技股份有限公司 | 一种转轮式自锁安全制动装置及其工作方法 |
| EP2287197A1 (en) * | 2009-08-21 | 2011-02-23 | Pierre Fabre Medicament | Anti-cMET antibody and its use for the detection and the diagnosis of cancer |
| HUE060454T2 (hu) | 2010-05-28 | 2023-03-28 | Chugai Pharmaceutical Co Ltd | Daganatellenes T-sejt-választ fokozó szer |
| WO2012003338A1 (en) | 2010-07-01 | 2012-01-05 | Takeda Pharmaceutical Company Limited | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET |
| CN103391773A (zh) | 2010-09-27 | 2013-11-13 | 埃克塞里艾克西斯公司 | 用于治疗去势抵抗性前列腺癌和成骨性骨转移的met和vegf的双重抑制剂 |
| CA2835242A1 (en) | 2011-06-30 | 2013-01-03 | Genentech, Inc. | Anti-c-met antibody formulations |
| CZ2011514A3 (cs) * | 2011-08-19 | 2013-01-23 | Invos, Spol. S R. O. | Biokontejner pro sber bioodpadu a komunálního odpadu |
| WO2013036872A1 (en) | 2011-09-09 | 2013-03-14 | Amgen Inc. | Use of c-met protein for predicting the efficacy of anti-hepatocyte growth factor ("hgf") antibodies in esophageal and gastric cancer patients |
| EP2758430A4 (en) | 2011-09-20 | 2015-06-03 | Lilly Co Eli | ANTI-C-MET ANTIBODY |
| JP6224586B2 (ja) | 2012-07-10 | 2017-11-01 | 武田薬品工業株式会社 | 注射用製剤 |
| EP2708556B1 (en) | 2012-09-12 | 2018-11-07 | Samsung Electronics Co., Ltd | Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases |
| WO2014153166A2 (en) * | 2013-03-14 | 2014-09-25 | Alder Biopharmaceuticals, Inc. | Therapeutic use of antibodies to hgf |
| US9481725B2 (en) | 2013-03-14 | 2016-11-01 | Alderbio Holdings, Llc | Antibodies to HGF and compositions containing |
| WO2015031578A1 (en) * | 2013-08-28 | 2015-03-05 | Abbvie Inc. | Hgf assay |
| EP3620531A4 (en) | 2017-05-02 | 2021-03-17 | National Center of Neurology and Psychiatry | METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS |
| WO2019078344A1 (ja) | 2017-10-20 | 2019-04-25 | 学校法人兵庫医科大学 | 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物 |
| WO2024229542A2 (pt) * | 2023-05-05 | 2024-11-14 | Instituto Butantan | Anticorpo monoclonal (mab) humano anti-fgf2, composição farmacêutica compreendendo o mesmo, uso do mesmo e kit para a detecção de câncer em uma amostra biológica compreendendo o referido mab |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US722041A (en) * | 1902-11-24 | 1903-03-03 | Mail Belting Company | Conveyer-belt. |
| JP2564486B2 (ja) | 1986-07-14 | 1996-12-18 | 修治 橋本 | 肝細胞増殖因子 |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| GB9003621D0 (en) | 1990-02-16 | 1990-04-11 | Imp Cancer Res Tech | Protein factor |
| GB9009548D0 (en) * | 1990-04-27 | 1990-06-20 | Celltech Ltd | Chimeric antibody and method |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| ATE185601T1 (de) | 1990-07-10 | 1999-10-15 | Cambridge Antibody Tech | Verfahren zur herstellung von spezifischen bindungspaargliedern |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| GB9110202D0 (en) * | 1991-05-10 | 1991-07-03 | Erba Carlo Spa | Truncated forms of the hepatocyte growth factor(hgf)receptor |
| LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
| US5837676A (en) | 1993-10-18 | 1998-11-17 | Long Island Jewish Medical Center | Use of scatter factor to enhance angiogenesis |
| US6498144B1 (en) | 1993-10-18 | 2002-12-24 | North Shore - Long Island Jewish Research Institute | Use of scatter factor to enhance angiogenesis |
| US5707624A (en) | 1994-06-03 | 1998-01-13 | The Regents Of The University Of Michigan | Treatment of Kaposi's sarcoma by inhibition of scatter factor |
| US5686292A (en) | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
| US5646036A (en) | 1995-06-02 | 1997-07-08 | Genentech, Inc. | Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies |
| US6214344B1 (en) * | 1995-06-02 | 2001-04-10 | Genetech, Inc. | Hepatocyte growth factor receptor antagonists and uses thereof |
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| WO1998000543A1 (en) | 1996-07-03 | 1998-01-08 | Genentech, Inc. | Hepatocyte growth factor receptor agonists and uses thereof |
| WO2000012560A1 (en) | 1998-08-28 | 2000-03-09 | Dendreon Corporation | Selective apoptosis of neoplastic cells by an hla-dr specific monoclonal antibody |
| WO2001034650A1 (en) | 1999-11-09 | 2001-05-17 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Heatlh And Human Services | Hgf-sf monoclonal antibody combinations |
| JP2004536605A (ja) | 2001-07-26 | 2004-12-09 | イーライ・リリー・アンド・カンパニー | インターロイキン１β抗体 |
| CA2472383A1 (en) | 2001-12-27 | 2003-07-17 | Van Andel Research Institute | Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor |
| WO2004019991A2 (en) | 2002-08-30 | 2004-03-11 | F. Hoffmann-La Roche Ag | Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma |
| US20040208876A1 (en) | 2003-04-18 | 2004-10-21 | Kim Kyung Jin | Monoclonal antibodies to hepatocyte growth factor |
| US7220410B2 (en) | 2003-04-18 | 2007-05-22 | Galaxy Biotech, Llc | Monoclonal antibodies to hepatocyte growth factor |
| AU2004252475A1 (en) | 2003-06-06 | 2005-01-06 | Genentech, Inc. | Modulating the interaction between HGF beta chain and c-met |
| ATE451115T1 (de) | 2003-07-07 | 2009-12-15 | Van Andel Res Inst | Hemmung der tumor-angiogenese durch eine kombination von thrombospondin-1 und hemmern des vaskulären endothel-wachstumsfaktors |
| PL1648998T3 (pl) * | 2003-07-18 | 2015-03-31 | Amgen Inc | Specyficzne czynniki wiążące czynnik wzrostu hepatocytów |
| KR100556660B1 (ko) | 2003-11-11 | 2006-03-10 | 국립암센터 | Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체 |
| MX2007015056A (es) | 2005-06-02 | 2008-03-11 | Galaxy Biotech Llc | Metodos para el tratamiento de tumores de cerebro con anticuerpos. |
| AR059922A1 (es) * | 2006-04-01 | 2008-05-07 | Galaxy Biotech Llc | Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos |
-
2004
- 2004-04-15 US US10/825,060 patent/US20040208876A1/en not_active Abandoned
- 2004-08-13 AU AU2004319276A patent/AU2004319276C1/en not_active Ceased
- 2004-08-13 EP EP04781281A patent/EP1734995B1/en not_active Expired - Lifetime
- 2004-08-13 BR BRPI0418745-8A patent/BRPI0418745A/pt not_active IP Right Cessation
- 2004-08-13 ZA ZA200609407A patent/ZA200609407B/xx unknown
- 2004-08-13 DK DK04781281.3T patent/DK1734995T3/da active
- 2004-08-13 CA CA2563080A patent/CA2563080C/en not_active Expired - Fee Related
- 2004-08-13 CN CNA200480042750XA patent/CN1964738A/zh active Pending
- 2004-08-13 AT AT04781281T patent/ATE473760T1/de active
- 2004-08-13 EP EP10160203A patent/EP2204191A1/en not_active Withdrawn
- 2004-08-13 ES ES04781281T patent/ES2346886T3/es not_active Expired - Lifetime
- 2004-08-13 DE DE602004028168T patent/DE602004028168D1/de not_active Expired - Lifetime
- 2004-08-13 KR KR1020067023964A patent/KR101072736B1/ko not_active Expired - Fee Related
- 2004-08-13 MX MXPA06011822A patent/MXPA06011822A/es active IP Right Grant
- 2004-08-13 RU RU2006140257/13A patent/RU2361879C2/ru not_active IP Right Cessation
- 2004-08-13 HR HR20100521T patent/HRP20100521T1/hr unknown
- 2004-08-13 SI SI200431468T patent/SI1734995T1/sl unknown
- 2004-08-13 WO PCT/US2004/026565 patent/WO2005107800A1/en active Application Filing
- 2004-08-13 PL PL04781281T patent/PL1734995T3/pl unknown
- 2004-08-13 PT PT04781281T patent/PT1734995E/pt unknown
- 2004-08-13 JP JP2007508323A patent/JP4594381B2/ja not_active Expired - Fee Related
- 2004-08-13 NZ NZ550324A patent/NZ550324A/en not_active IP Right Cessation
-
2006
- 2006-10-05 IL IL178474A patent/IL178474A/en not_active IP Right Cessation
- 2006-10-19 CR CR8698A patent/CR8698A/es unknown
- 2006-11-14 NO NO20065227A patent/NO20065227L/no not_active Application Discontinuation
-
2007
- 2007-02-23 US US11/710,009 patent/US7494650B2/en not_active Expired - Fee Related
- 2007-06-13 US US11/818,305 patent/US7687063B2/en not_active Expired - Fee Related
-
2008
- 2008-12-22 US US12/342,059 patent/US20090104192A1/en not_active Abandoned
-
2010
- 2010-08-03 JP JP2010174810A patent/JP2011012067A/ja not_active Withdrawn
- 2010-08-30 CY CY20101100789T patent/CY1110783T1/el unknown
-
2011
- 2011-06-14 US US13/160,444 patent/US20120064066A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2006140257A (ru) | Моноклональные антитела к фактору роста гепатоцитов | |
| Gandullo-Sánchez et al. | HER3 in cancer: from the bench to the bedside | |
| RU2421464C2 (ru) | Человеческие антитела к il-13 и их терапевтическое применение | |
| JP2025032085A (ja) | 線維芽増殖因子受容体２に対するモノクローナル抗体 | |
| JP6325527B2 (ja) | ヒト化ｐａｎ−ｈｅｒ抗体組成物 | |
| RU2007133108A (ru) | АНТИТЕЛА, СВЯЗЫВАЮЩИЕСЯ С EphA2, И МЕТОДЫ ИХ ИСПОЛЬЗОВАНИЯ | |
| Huang et al. | Targeted therapy for malignant glioma patients: lessons learned and the road ahead | |
| RU2006139073A (ru) | Способы лечения боли, обусловленной раком кости, путем введения антагониста фактора роста нервов | |
| ATE482722T1 (de) | Therapeutische verwendung von anti-cs1- antikörpern | |
| RU2413735C2 (ru) | Антитела и родственные молекулы, связывающиеся с белками 161p2f10b | |
| RU2008143318A (ru) | Гуманизированные моноклональные антитела к фактору роста гепатоцитов | |
| JP2017512765A5 (ru) | ||
| LTC2380910I2 (lt) | Antigeną surišančios molekulės su padidintu Fc receptoriaus prisirišimo gimingumu ir efektorine funkcija | |
| RU2008137764A (ru) | Способы предотвращения и лечения амилоидных заболеваний | |
| JP2016188209A5 (ru) | ||
| NZ712762A (en) | Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r | |
| DK1624892T3 (da) | Terapeutisk anvendelse af anti-CSI-antistoffer | |
| RU2013141976A (ru) | Новые модуляторы и способы их применения | |
| RU2016144176A (ru) | Биспецифические антитела к her2 | |
| JP2011521966A5 (ru) | ||
| JP2007536932A5 (ru) | ||
| JP5972573B2 (ja) | 塩基性線維芽細胞成長因子に対するモノクローナル抗体 | |
| JP2020533965A5 (ru) | ||
| JP2020531003A5 (ru) | ||
| US20150110788A1 (en) | Bispecific antibodies with an fgf2 binding domain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20160814 |